Sanofi Scores FDA Approval For Flu-Shot Facility In US

The FDA has approved Sanofi SA's SNY newly completed plant in Swiftwater, Pennsylvania.
The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.
With $425 million of investment, the opening of the new plant will require Sanofi to add up to 200 employees.
Fluzone High-Dose is a quadrivalent vaccine targeting four flu strains.
Price Action: SNY shares are down 0.43% at $53.19 during the market trading session on the last check Thursday.